All In Biotech

Drug Trial Radar · NCT03219268

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms

Last checked: Nov 20, 2026Latest source record: Dec 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

277

Actual

Start

Aug 18, 2017

Primary completion

Feb 8, 2023

Study completion Feb 8, 2023

Sponsor

Lead sponsor
MacroGenicsIndustry
Sponsor type
Industry
First posted
Jul 17, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary goal of this Phase 1 study is to characterize the safety and tolerability of tebotelimab and establish the maximum tolerated dose (MTD) of tebotelimab in advanced solid tumors, and tebotelimab in combination with margetuximab in HER2+ advanced solid tumors. Pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of tebotelimab will also be assessed.

Conditions

  • Advanced Solid Tumors
  • Hematologic Neoplasms
  • Ovarian Cancer
  • HER2-positive Advanced Solid Tumors
  • Non Small Cell Lung Cancer
  • Small-cell Lung Cancer
  • Squamous Cell Carcinoma of Head and Neck
  • Cholangiocarcinoma
  • Cervical Cancer
  • TNBC - Triple-Negative Breast Cancer

Interventions

  • tebotelimab 1 mgBiological

    1 mg IV every other week

  • tebotelimab 3 mgBiological

    3 mg IV every other week

  • tebotelimab 10 mgBiological

    10 mg IV every other week

  • tebotelimab 30 mgBiological

    30 mg IV every other week

  • tebotelimab 120 mgBiological

    120 mg IV every other week

  • tebotelimab 300 mgBiological

    300 mg IV every other wee

  • tebotelimab 400 mgBiological

    400 mg IV every other wee

  • tebotelimab 600 mgBiological

    600 mg IV every other week

  • tebotelimab 800 mgBiological

    800 mg IV every other week

  • tebotelimab 1200 mgBiological

    1200 mg IV every other week

  • margetuximabBiological

    15 mg/kg IV every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Treatment-Emergent Adverse Events (TEAE) as assessed by CTCAE v4.03 (tebotelimab monotherapy)Time frame: up to 24 months
  2. Number of participants with Treatment-Emergent Adverse Events as assessed by CTCAE v4.03 (tebotelimab plus margetuximab)Time frame: up to 24 months

Locations

40 sites in 8 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California

  • UCLA Hematology & Oncology Clinic

    Los Angeles, California

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California

  • Florida Cancer Specialists & Research Institute

    Sarasota, Florida

  • University of Chicago Medicine

    Chicago, Illinois

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland

  • Massachusetts General Hospital and Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Duke University Medical Center

    Durham, North Carolina

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Stephenson Cancer Center, The University of Oklahoma

    Oklahoma City, Oklahoma

  • University of Pennsylvania, Abramson Cancer Center

    Philadelphia, Pennsylvania

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • The University of Texas M.D. Anderson Cancer Center

    Houston, Texas

  • St Vincent's Hospital Sydney

    Darlinghurst, New South Wales, Australia

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia

  • Southern Medical Day Care Centre

    Wollongong, New South Wales, Australia

  • Austin Health Melbourne

    Heidelberg, Victoria, Australia

  • "Complex Oncology Center - Burgas" EOOD

    Burgas, Bulgaria

  • "Acibadem City Clinic Multiprofile Hospital for Active Treatment Tokuda" EAD, Sofia

    Sofia, Bulgaria

  • Multiprofile Hospital for Active Treatment "Serdika" EOOD, Sofia

    Sofia, Bulgaria

  • Prince of Wales Hospital

    Shatin, Hong Kong

  • Med-Polonia Sp. z o.o.

    Poznan, Poland

  • Pratia MCM Kraków

    Krakow, Lesser Poland Voivodeship, Poland

  • BioVirtus Research Site Sp. Z o.o. / Biovirtus Centrum Medyczne

    Józefów, Masovian Voivodeship, Poland

  • Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy

    Warsaw, Masovian Voivodeship, Poland

  • Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy

    Warsaw, Masovian Voivodeship, Poland

  • Vall d'Hebron Institute of Oncology

    Barcelona, Spain

  • Hospital Ruber Internacional

    Madrid, Spain

  • START Madrid-CIOCC, Hospital HM Sanchinarro

    Madrid, Spain

  • King Chulalongkorn Memorial Hospital

    Bangkok, Thailand

  • Maharaj Nakorn Chiang Mai Hospital

    Chiang Mai, Thailand

  • Songklanagarind Hospital

    Songkhla, Thailand

  • Communal Non-profit Enterprise "City Clinical Hospital #4" of Dnipro City Council

    Dnipro, Ukraine

  • Communal Nonprofit Enterprise "Prykarpatsky Clinical Oncological Centre of Ivano-Frankivska Regional Council"

    Ivano-Frankivsk, Ukraine

  • Municipal Non-Profit Enterprise of Sumy Regional Council "Sumy Regional Clinical Oncology Dispensary"

    Sumy, Ukraine

  • Communal Nonprofit Enterprise "Central City Clinical Hospital of Uzhhorod City Council", City Oncology Center, State Higher Educational Institution <<Uzhhorod National University>>

    Uzhhorod, Ukraine

  • Communal Nonprofit Enterprise "Cherkassy Regional Oncology Dispensary" of Cherkassy Regional Council

    Cherkassy, Cherkasy Oblast, Ukraine

  • Communal Nonprofit Enterprise Podillia Regional Center of Oncology of Vinnytsia Regional Council

    Vinnytsia, Vinnytsa Region, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.